Today: 9 June 2026
Waaree Energies share price in focus: Jefferies trims target as Q3 surge meets export worries
26 January 2026
2 mins read

Waaree Energies share price in focus: Jefferies trims target as Q3 surge meets export worries

BENGALURU, Jan 26, 2026, 07:45 IST — Market has closed.

  • Waaree Energies ended at 2,599.30 rupees, slipping 1.6% just before India’s market reopened after the holiday.
  • Jefferies lowered its target price to 2,185 rupees but maintained an underperform rating despite the Q3 beat.
  • Order execution, export challenges, and the company’s large capex commitments are all under investor scrutiny.

Waaree Energies shares face a crucial test as Indian markets open, following a downgrade by Jefferies that clashed with the stock’s recent pause near its breakout. The stock ended Friday at 2,599.30 rupees, slipping 1.6%, after bouncing between 2,586 and 2,693.

The halt in trading hits both bulls and bears at a tricky time. Waaree’s Q3 results and its upcoming project pipeline have pushed the stock back into the spotlight within solar manufacturing, but the next move is shaping up to be more complicated than the initial earnings-driven surge.

Jefferies cut its target price to 2,185 rupees from 2,295 while sticking with an “underperform” rating, despite noting a volume-driven earnings beat. The broker flagged a steep drop in exports following U.S. tariffs and cautioned that anti-dumping and countervailing duties—import taxes that can squeeze shipments and margins—might weigh on the stock as its order book increasingly focuses on the U.S. NDTV Profit

Waaree reported revenue from operations of 7,565 crore rupees for the quarter ending December, alongside a profit after tax (PAT) of 1,106 crore rupees. Operating EBITDA, which excludes interest, tax, depreciation, and amortisation, stood at 1,928 crore rupees. The company’s order book sits at around 60,000 crore rupees. It also revealed plans for capital expenditure exceeding 25,000 crore rupees. During the quarter, Waaree commissioned new module capacity in Gujarat and launched a 3.05-gigawatt inverter production line. Key order wins included 5.3 GW of module contracts and a 100 crore rupee transformer supply deal.

During the earnings call, CEO Amit Paithankar told analysts, “We are negotiating with various suppliers across geographies to ensure equipment availability.” Abhishek Pareek, group head for finance, added, “Our renewable power infrastructure offers turnkey solutions, including land acquisition and connectivity, for large institutions and private equity players.” Investing.com Canada

There’s a sharper downside risk if export conditions and regulations tighten. An exchange filing flagged uncertainty stemming from a U.S. Customs and Border Protection probe related to exports to the U.S., along with mentioning an ongoing income tax investigation at the company’s India operations since November. No further financial adjustments have been made until these investigations conclude.

The sector mood hasn’t eased jitters. Waaree surged over 13% Thursday post its quarterly results, fueling a wider rally in renewables that lifted Suzlon, Premier Energies, and Vikram Solar too—before buying grew more cautious.

Traders will be watching closely to see if post-break flows position Waaree as a growth and capex play or view it more as a proxy for export risks. Early moves in response to brokerage notes will be key, along with whether buyers jump in during dips or hold back until the U.S. trade and duty outlook becomes clearer.

Investors will zero in on execution—how quickly new lines scale up, if the domestic mix can offset international swings, and whether order conversion matches the pace of capacity expansion. Any delays will hit margins and working capital before they affect headline revenue.

India’s stock markets remain closed Monday for Republic Day. Trading resumes Tuesday, Jan. 27, and Waaree’s initial post-holiday numbers are expected to influence the week’s direction.

Stock Market Today

  • SailPoint Q1 Earnings Beat Estimates Amid Revenue Growth
    June 9, 2026, 10:14 AM EDT. SailPoint, Inc. (SAIL) reported Q1 earnings of $0.05 per share, surpassing the Zacks Consensus Estimate of $0.04 by 17.65%. Revenue increased to $280.14 million, beating estimates by 1.41% and up from $230.47 million a year ago. Despite earnings surprises and revenue growth, SailPoint shares have declined 12.6% year-to-date against the S&P 500's 8.2% rise. The company holds a Zacks Rank #3 (Hold), indicating expected market-aligned performance. Consensus estimates forecast Q2 EPS of $0.08 on $310.79 million revenue and fiscal year EPS of $0.32 on $1.27 billion revenue. Industry trends in the Zacks Internet-Software sector will influence future stock performance. Investors await management's commentary for guidance on sustainability.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
MinebeaMitsumi stock price slides in Tokyo as yen firms; Feb. 5 earnings loom
Previous Story

MinebeaMitsumi stock price slides in Tokyo as yen firms; Feb. 5 earnings loom

Netflix to Paramount: Your Warner Bros bid “doesn’t pass the sniff test” as takeover clock ticks
Next Story

Netflix to Paramount: Your Warner Bros bid “doesn’t pass the sniff test” as takeover clock ticks

Go toTop